Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.

Patients with prostate cancer fared better following treatment with magnetic resonance-guided focused ultrasound focal therapy than with radical prostatectomy or radiation therapy, shows study presented at 2021 AUA Annual Meeting.

Treating patients with brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy resulted in strong efficacy and encouraging tolerability in early-stage, unfavorable-risk Hodgkin lymphoma.

Nivolumab with or without ipilimumab improved survival over ipilimumab alone in patients with previously untreated advanced melanoma.

While CAR T-cell therapy is causing landmark changes to difficult-to-treat blood cancer populations, most patients have experienced some adverse events in clinical trials.

The PARP inhibitor rucaparib was beneficial and tolerable for patients with BRCA-positive, metastatic, castration-resistant prostate cancer.

Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

During his presentation, Michael A. Postow, MD, briefly reviewed the latest updates with immunotherapy and other targeted treatments in melanoma reported during the 2020 ASCO Virtual Scientific Program.

Efforts are being made to address remaining questions in the realm of BRAF-mutant melanoma, according to Charles L. Sawyers, MD.

Pembrolizumab combined with trastuzumab and chemotherapy demonstrated clinical activity in patients with HER2-positive metastatic esophagogastric cancer.

The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t follow the passage of the Affordable Care Act (ACA) of 2010, a study found.

Preliminary durability results of the EV-103 study show that the combination of enfortumab vedotin and pembrolizumab may be a promising option for patients with locally advanced or metastatic urothelial carcinoma.

Two new single agents led to brain penetrance and 2-hydroxyglutarate (2-HG) suppression in patients with low-grade glioma who harbor IDH1 mutations, according to updated findings.